Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT: Taldefgrobep Alfa in Spinal Muscular Atrophy
NCT05337553Phase 3Active, not recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Jul 2022
- Primary completion
- Sep 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 3 trial of taldefgrobep alfa in spinal muscular atrophy (SMA), sponsored by Biohaven Ltd.. Started Jul 2022; status: active, not recruiting.
02
Drugs
taldefgrobep alfa
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05337553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337553.